A responsive disulfide bond switch aptamer prodrug exhibiting enhanced stability and anticancer efficacy

Bioorg Med Chem Lett. 2024 Apr 5:129729. doi: 10.1016/j.bmcl.2024.129729. Online ahead of print.ABSTRACTAptamers have shown significant potential in treating diverse diseases. However, challenges such as stability and drug delivery limited their clinical application. In this paper, the development of AS1411 prodrug-type aptamers for tumor treatment was introduced. A Short oligonucleotide was introduced at the end of the AS1411 sequence with a disulfide bond as responsive switch. The results indicated that the aptamer prodrugs not only enhanced the stability of the aptamer against nuclease activity but also facilitated binding to serum albumin. Furthermore, in the reducing microenvironment of tumor cells, disulfide bonds triggered drug release, resulting in superior therapeutic effects in vitro and in vivo compared to original drugs. This paper proposes a novel approach for optimizing the structure of nucleic acid drugs, that promises to protect other oligonucleotides or secondary structures, thus opening up new possibilities for nucleic acid drug design.PMID:38583786 | DOI:10.1016/j.bmcl.2024.129729

Source: Bioorganic and Medicinal Chemistry Letters - April 7, 2024 Category: Chemistry Authors: Xiao Dong Zhe Zhang Tangna Zhao Zuyi Chen Jia Wang Liang Xu Aiping Zhang Source Type: research